poisar

Stocks · News reference

Ensysce Biosciences Q2 EPS $(0.20) Beats $(0.50) Estimate, Sales $1.164M Beat $1.000M Estimate

BenzingaBenzinga Newsdesk

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.50) by 60 percent. This is a 74.68 percent increase over losses of $(0.79) per share from

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Fiscal.ai

    Ensysce Biosciences Announces CEO Transition

    Ensysce Biosciences announced that CEO Lynn Kirkpatrick will transition to the role of Chief Operating Officer, with President James Morrisson set to assume the CEO position following the company's annual meeting on December 14, 2026.